Table 2.
Patient characteristics and outcomes by IDH mutation type
| IDH1/2 WT (n = 3946) | IDH1-R132C (n = 179) | IDH1-R132H (n = 177) | IDH1 other (n = 67) | IDH2-R172 (n = 110) | IDH2-R140 (n = 446) | P | |
|---|---|---|---|---|---|---|---|
| Age, median (IQR), y | 55 (44-65) | 62 (53-69) | 54 (44-65) | 60 (51-67) | 61 (50-66) | 59 (51-68) | <.0001 |
| Disease status | .0553 | ||||||
| De novo | 3168/3913 (81) | 140/179 (78.2) | 156/176 (88.6) | 57/67 (85.1) | 94/110 (85.5) | 368/441 (83.4) | |
| Secondary AML | 511/3913 (13.1) | 28/179 (15.6) | 13/176 (7.4) | 9/67 (13.4) | 14/110 (12.7) | 51/441 (11.6) | |
| tMN | 234/3913 (6) | 11/179 (6.1) | 7/176 (4) | 1/67 (1.5) | 2/110 (1.8) | 22/441 (5) | |
| WBC count, median (IQR), (×109/L) | 15.3 (3.9-50.5) | 4.3 (1.6-25.3) | 22.5 (3.8-67) | 15.2 (3.6-51.9) | 2.3 (1.2-9.2) | 16.8 (4.1-56.6) | <.0001 |
| Platelets, median (IQR), (×109/L) | 51 (28-92) | 55 (30-110) | 74 (40-124) | 58 (33-137) | 82 (42-158) | 65 (37-117) | <.0001 |
| Bone marrow blasts, median (IQR), % | 63 (40-80) | 71 (55-86) | 70 (51-84) | 80 (60-89) | 64 (43-81) | 70 (44-85) | <.0001 |
| Normal karyotype | 1897/3717 (51) | 101/159 (63.5) | 132/158 (83.5) | 44/61 (72.1) | 58/101 (57.4) | 304/412 (73.8) | <.0001 |
| Complex karyotype | 424/2949 (14.4) | 8/127 (6.3) | 5/127 (3.9) | 1/48 (2.1) | 3/74 (4.1) | 11/296 (3.7) | <.0001 |
| Trisomy 8 | 313/3717 (8.4) | 2/159 (13.8) | 7/158 (4.4) | 5/61 (8.2) | 16/101 (15.8) | 24/412 (5.8) | .0012 |
| ELN 2017 risk | <.0001 | ||||||
| Favorable | 1234/3640 (33.9) | 33/152 (21.7) | 98/155 (63.2) | 31/58 (53.4) | 2/100 (2) | 177/405 (43.7) | |
| Intermediate | 1280/3640 (35.2) | 78/152 (51.3) | 44/155 (28.4) | 21/58 (36.2) | 63/100 (63) | 141/405 (34.8) | |
| Adverse | 1126/3640 (30.9) | 41/152 (27) | 13/155 (8.4) | 6/58 (10.3) | 35/100 (35) | 87/405 (21.5) | |
| NPM1 mutated | 1110/3914 (28.4) | 43/178 (24.2) | 125/176 (71) | 43/67 (64.2) | 2/110 (1.8) | 220/445 (49.4) | <.0001 |
| FLT3-ITD mutated | 890/3928 (22.7) | 18/178 (10.1) | 47/176 (26.7) | 18/67 (26.9) | 5/110 (4.5) | 108/446 (24.2) | <.0001 |
| FLT3 ratio, median (IQR) | 0.6 (0.2-0.8) | 0.3 (0.1-0.5) | 0.7 (0.3-0.9) | 0.4 (0.2-0.7) | 0.6 (0.6-0.6) | 0.5 (0.2-0.7) | .1018 |
| CEBPA mutated | 288/3886 (7.4) | 7/177 (4) | 1/175 (0.6) | 4/67 (6) | 6/110 (5.5) | 17/442 (3.8) | .0005 |
| IDH VAF, median (IQR) | — | 37.2 (27.6-41) | 37.6 (25.4-42) | 40 (28.6-47.6) | 38.3 (31.2-45) | 39 (32.8-45) | .0008 |
| Allogeneic HSCT in CR1 | 732/3946 (18.6) | 25/179 (14) | 23/177 (13) | 9/67 (13.4) | 21/110 (19.1) | 65/446 (14.6) | .0674 |
| CR | 2892/3946 (73.3) | 110/179 (61.5) | 136/177 (76.8) | 46/67 (68.7) | 80/110 (72.7) | 327/446 (73.3) | .0143 |
| OS, median (95% CI), mo | 19.7 (18.1-21.4) | 14.7 (12.2-21.9) | 23 (16.4-36.1) | 18.7 (13.3-61.4) | 25.6 (21.6-46.3) | 18.9 (15.7-27.4) | .2407 |
CR1, first CR; HSCT, hematopoietic stem cell transplantation; tMN, therapy-associated myeloid neoplasm; VAF, variant allele fraction.